WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Astellas and Ambrx initiate collaboration for discovery and development of antibody drug conjugates for oncology

Details
Business
07 April 2013
AstellasAstellas Pharma Inc. (Tokyo: 4503, "Astellas") entered into a collaboration with Ambrx Inc. ("Ambrx") for the discovery and development of novel antibody drug conjugates ("ADCs"). ADCs allow for the targeted delivery of drugs to the target tissue. Ambrx creates optimized ADCs using its site-specific conjugation technology along with proprietary linkers and payloads.
Read more ...

Luqa Pharmaceuticals and Stratpharma enter into an exclusive agreement

Details
Business
08 August 2012
Luqa Pharmaceuticals announced today that it has entered into an exclusive agreement with Stratpharma AG of Switzerland to promote, sell, and distribute Strataderm®, in the People's Republic of China.
Read more ...

Sanofi and Astellas to dissolve sanofi-aventis Yamanouchi Pharmaceutical Inc.

Details
Business
29 February 2012
Astellas Pharma Inc.Sanofi and Astellas Pharma Inc. announced that the two companies agreed to dissolve sanofi-aventis Yamanouchi Pharmaceutical Inc., a joint company of Sanofi and Astellas.
Read more ...

Forest Laboratories Completes Acquisition of Clinical Data, Inc.

Details
Business
14 April 2011
Forest LaboratoriesForest Laboratories, Inc. (NYSE: FRX) ("Forest") has successfully completed its acquisition of Clinical Data, Inc. (NASDAQ: CLDA) ("Clinical Data") by means of what is known as a short-form merger under Delaware law.
Read more ...

Forest Laboratories, Inc. Finalizes Previously Disclosed Settlement of U.S. Government Investigations

Details
Business
16 September 2010
Forest Laboratories, Inc.Forest Laboratories, Inc. (NYSE: FRX) has finalized a previously reported agreement-in-principle to resolve all aspects of the investigations led by the United States Department of Justice (DOJ) and the United States Attorney's Office for the District of Massachusetts that began in January 2004 relating to past marketing, sales, and other activities in connection with Celexa(R), Lexapro(R), and a formulation of Levothroid(R) that Forest ceased distributing in 2003.
Read more ...

Covex S.A. creates 2000 jobs with the onset of a new agroindustrial project in Latin America

Details
Business
17 May 2010
Covex S.A.Covex S.A., leader in the manufacture of products aimed at improving cerebral functions, successfully reaches the first stage of its introduction in Latin America, as it begins to harvest medicinal plants on an industrial scale, for the onset of its new agroindustrial expansion.
Read more ...

Luitpold Pharmaceuticals, Inc. Acquires PharmaForce, Inc.

Details
Business
06 January 2010
Daiichi Sankyo Co., Ltd.Luitpold Pharmaceuticals, Inc., a New York based U.S. Company of Daiichi Sankyo Co., Ltd. (Corporate Headquarters: Tokyo, Japan) and PharmaForce, Inc., (Columbus, Ohio, USA), a privately-held fullyintegrated specialty injectable pharmaceutical company, announced today that PharmaForce has been acquired by Luitpold.
Read more ...

More Pharma News ...

  1. Onyx Pharmaceuticals to Acquire Proteolix, Inc.
  2. Forest Laboratories and AstraZeneca to Co-Develop and Commercialize a Next Generation Anti-Infective
  3. Schering-Plough announces collaboration with World Health Organization
  4. DHL COLDCHAIN offers fast, reliable and flexible solutions designed for the Life Science Industry
  5. FivePrime and Pfizer Enter Oncology and Diabetes Collaboration
  6. Grindeks JSC is opening new representative office in Uzbekistan
  7. Dr. Reddy's acquires Jet Generici Srl. Acquisition to establish Generics business in Italy
  • Start
  • Prev
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • Next
  • End

Business & Industry

  • GSK completes acquisition of Sierra Oncology
  • Pfizer and BioNTech announce new agreement with U.S. government to provide additional doses of COVID-19 vaccine
  • Bayer opens new Research & Innovation Center in Boston-Cambridge demonstrating its commitment to precision oncology
  • New Novartis extension phase data show nearly 80% of RMS patients treated with Kesimpta® (ofatumumab) had no evidence of disease activity (NEDA-3)
  • Pfizer and BioNTech announce Omicron-adapted COVID-19 vaccine candidates demonstrate high immune response against Omicron

Research & Development

  • Inhalable COVID-19 vaccine shows promise in rodent model
  • Researchers discover new leukemia-killing compounds
  • Oral antiviral drug effective against respiratory syncytial virus (RSV) identified by researchers
  • Biomarkers found that could be drug targets against a deadly form of brain cancer
  • COVID-19 rebound after taking Paxlovid likely due to insufficient drug exposure
  • Novel drug combo activates natural killer cell immunity to destroy cancer cells
  • Broadly neutralizing antibodies could provide immunity against SARS-CoV-2 variants

Conferences & Events

  • New approach to treatment of deadly kidney cancer
  • SAE Media Group proudly presents the 2nd Annual Aseptic Processing Conference
  • Pharma join together to achieve new standards in digital and patient innovation for clinical transformation
  • SMi's 22nd Annual Pain Therapeutics Conference
  • SMi Group Introduces the 4th Annual Injectable Drug Delivery Conference 2022
  • SMi's 5th Annual Pharmaceutical Microbiology East Coast Conference
  • SMi's 3rd Annual AI in Drug Discovery Conference

Regulatory Affairs

  • FDA approves first systemic treatment for alopecia areata
  • FDA urges drug manufacturers to develop risk management plans to promote a dtronger, resilient drug supply chain
  • FDA limits use of Janssen COVID-19 vaccine to certain individuals
  • EMA establishes Cancer Medicines Forum with academia to optimise cancer treatments in clinical practice
  • FDA approves first generic of Symbicort to treat asthma and COPD
  1. You are here:  
  2. Home
  3. Business
  4. Leiden University Medical Center and Intravacc to start clinical trial with new intranasal corona vaccine

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2022. All Rights Reserved.